Navigation Links
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Date:11/5/2009

s of approximately $139.7 million, compared with $154.7 million as of December 31, 2008.

Results for the Nine Months Ended September 30, 2009

InterMune also reported results from operations for the nine months ended September 30, 2009. The net loss for the period was $87.4 million, or $2.00 per share, compared with a net loss of $72.7 million, or $1.87 per share, in the first nine months of 2008.

Total revenue in the first nine months of 2009 was $42.1 million, compared with total revenue of $40.8 million in the same period of 2008, an increase of 3 percent. Actimmune revenue totaled $19.6 million in the first nine months of 2009, compared with $23.3 million of Actimmune revenue in the first nine months of 2008, a decrease of approximately 16 percent, reflecting lower off-label sales of Actimmune for the treatment of IPF, which InterMune does not promote. Revenue from the collaboration with Roche was $22.5 million in the first nine months of 2009, compared with $17.5 million in the same period of 2008. Collaboration revenue in the first nine months of 2009 included a $20.0 million milestone payment from Roche in connection with the start of the Phase 2b clinical trial program of ITMN-191, which was initiated in August. Collaboration revenue in the first nine months of 2008 included a $15.0 million development milestone payment received in the third quarter of 2008.

R&D expenses were $68.0 million in the first nine months of 2009, a 13 percent decrease compared to $78.0 million in the same period of 2008. This decrease in R&D expenses was primarily due to the completion of the Phase 3 CAPACITY program in early 2009, partially offset by increased expenses associated with: the RECAP pirfenidone study, the INFORM-1 and Phase 2b studies with ITMN-191 and the preparation of the NDA and MAA for pirfenidone. G&A expenses of $26.9 million in the first nine months of 2009 were approximately 19 percent highe
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... 12, 2014 Sepsis is a life ... worldwide.  Education and awareness are fundamental to improving ... marks Sepsis Awareness Month and September 13 th ... Sepsis Alliance, "Sepsis, the body,s toxic reaction to ... every year, and thousands more are left with ...
(Date:9/11/2014)... , September 11, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/lqkmlx/radio_frequency ) has announced the ... Identification (RFID) Market in Healthcare (Tags, ... Industry Analysis, Size, Share, Growth, Trends ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:9/11/2014)... , Sept. 11, 2014 Array BioPharma Inc. ... focused on the discovery, development and commercialization of ... cancer, today announced the appointment of Victor ... Sandor will be responsible for leading clinical, medical ... portfolio, including binimetinib, a MEK inhibitor in Phase ...
Breaking Medicine Technology:Nanomix Supports Sepsis Awareness 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 2Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 4
(Date:9/13/2014)... 2014 Ticket Down is a ... This beloved pop-rock group that originally formed in 1994 in ... Fans of the group had been anticipating a new album ... were excited yet about the release of their new album, ... announced a massive worldwide tour beginning in the United States ...
(Date:9/13/2014)... 2014 Healthcare employers, hospitals, insurance ... to operators in the Healthcare Consultants ... “Over the past five years, demand for healthcare ... the healthcare sector and the changing regulatory environment,” ... the 2010 Patient Protection and Affordable Care Act ...
(Date:9/13/2014)... 13, 2014 Termlifeinsurancequotesonline.org has released ... life insurance for smokers. , Smokers can now ... a medical examination. The only application process clients have ... answering a few medical questions. , Since smoking ... plans before making a decision. Comparing life insurance policies ...
(Date:9/13/2014)... Researchers say they,ve tracked specific activity in the human ... whether imagination and memory were distinct processes, so a ... to explore the issue. "I was thinking a ... myself in the future, and I started wondering how ... said in a university news release. "I wondered ...
(Date:9/13/2014)... Bedros Keuilian, founder of the internationally franchised Fit Body ... always been an advocate of using Groupon as a marketing ... but the post explains that this isn’t true; but the ... lot of people think of Groupon deals as a way ... special and the only thing they’re thinking of is the ...
Breaking Medicine News(10 mins):Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 2Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 3Health News:Healthcare Consultants in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Healthcare Consultants in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Smokers Can Qualify for Life Insurance Without Taking a Medical Exam 2Health News:Scientists Watch Imagination at Work in the Brain 2Health News:Renegade Fitness Marketing Expert Reveals How Personal Trainers Can Use Groupon More Effectively to Sign New Clients 2Health News:Renegade Fitness Marketing Expert Reveals How Personal Trainers Can Use Groupon More Effectively to Sign New Clients 3
... (AIs) prevent the conversion of androgens to estrogens, and could ... This study of 36 pre-menopausal women consisted of a cross-over ... wine and white wine in their effects on AIs. ... white wine (or vice versa), each beverage for a one-month ...
... HealthDay Reporter , WEDNESDAY, Jan. 18 (HealthDay News) ... to have successfully cleared the hepatitis C virus in ... more, the approach seems to work without the need ... causes serious side effects in many patients. Scientists ...
... , TUESDAY, Jan. 17 (HealthDay News) -- An experimental anti-blood-clotting ... as Plavix in the days before heart surgery, a new ... to have the potential to serve as a "bridge" medication ... procedures such as coronary artery bypass grafting, the study authors ...
... into the treatment, prognosis and early detection of gastrointestinal ... annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, ... Four important studies were highlighted today in a ... Patients at High Risk for Esophageal Cancer: Newly found ...
... of care advances, more infants and children with ... are left with lifelong neurologic impairment. A ... million pediatric hospitalizations in the U.S. now shows ... small part of the overall population, account for ...
... By Serena Gordon HealthDay Reporter , TUESDAY, Jan. ... one in six American children are obese, new government reports show. ... the past 12 years, those rates have remained roughly the same. ... some time. And, this is not just the U.S. It,s happening ...
Cached Medicine News:Health News:New Drug Combo for Hepatitis C Shows Promise 2Health News:New Drug Combo for Hepatitis C Shows Promise 3Health News:Experimental Blood Thinner Given Before Surgery Shows Benefit 2Health News:2012 Gastroinstestinal Cancers Symposium reveals new advances aimed at improving treatment, prognosis and detection of GI cancers 2Health News:Neurologically impaired children dependent on children's hospitals 2Health News:Americans Aren't Getting Any Skinnier 2Health News:Americans Aren't Getting Any Skinnier 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: